亚洲精品国产v片在线观看,欧美v日韩v国产综合,亚洲av片一区二区三区不卡不,日韩欧美中文在线播放

行業(yè)產(chǎn)品

  • 行業(yè)產(chǎn)品

上海瑞齊生物科技有限公司


當(dāng)前位置：上海瑞齊生物科技有限公司>>一抗>>Anti-Tri Methyl-Histone H3 （Lys36）*基組蛋白H3抗體

Anti-Tri Methyl-Histone H3 （Lys36）*基組蛋白H3抗體

返回列表頁
參  考  價(jià)面議
具體成交價(jià)以合同協(xié)議為準(zhǔn)

產(chǎn)品型號

品       牌

廠商性質(zhì)生產(chǎn)商

所  在  地上海

聯(lián)系方式：楊經(jīng)理查看聯(lián)系方式

更新時(shí)間：2017-09-12 15:54:45瀏覽次數(shù)：181次

聯(lián)系我時(shí)，請告知來自 環(huán)保在線

經(jīng)營模式：生產(chǎn)廠家

商鋪產(chǎn)品：88條

所在地區(qū)：上海上海

聯(lián)系人：楊經(jīng)理

產(chǎn)品簡介

Anti-Tri Methyl-Histone H3 (Lys36)*基組蛋白H3抗體

詳細(xì)介紹

 Anti-Tri Methyl-Histone H3 （Lys36）*基組蛋白H3抗體

專業(yè)提供 Anti-Tri Methyl-Histone H3 （Lys36）*基組蛋白H3抗體廣泛應(yīng)用于免疫組化，ELISA，Western Blot  IHC-F（免疫組化－冰凍切片），IHC-P （免疫組化－石蠟切片）IP（免疫沉淀）， Flow-Cyt等方面。 

產(chǎn)品編號  Rs-3768R
英文名稱  Anti-Tri Methyl-Histone H3 （Lys36）
中文名稱  *基組蛋白H3抗體
別    名  H3 histone family member E pseudogene; H3F3; HIST3H3; Histone H3 3 pseudogene. 
抗體介紹：Modulation of the chromatin structure plays an important role in the regulation of transcription in eukaryotes. The nucleosome, made up of four core histone proteins （H2A, H2B, H3 and H4）, is the primary building block of chromatin. The N-terminal tail of core histones undergoes different posttranslational modifications including acetylation, phosphorylation and methylation. These modifications occur in response to cell signal stimuli and have a direct effect on gene expression. In most species, the histone H2B is primarily acetylated at lysines 5, 12, 15 and 20. Histone H3 is primarily acetylated at lysines 9, 14, 18 and 23. Acetylation at lysine 9 appears to have a dominant role in histone deposition and chromatin assembly in some organisms. Phosphorylation at Ser10 of histone H3 is tightly correlated with chromosome condensation during both mitosis and meiosis.
產(chǎn)品類型  一抗 甲基化抗體 
抗體來源  Rabbit 
克隆號  Polyclonal
交叉反應(yīng)  hu, rat, mo
蛋白分子量  Predicted Molecular Weight: 15kDa
性狀  Lyophilized or Liquid
濃度  1mg/1ml
免疫原  KLH conjugated synthetic peptide derived from hu Histone H3 （Tri Methyl Lys36）.
亞型  IgG
純化方法  affinity purified by Protein A
儲(chǔ)存液  Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
產(chǎn)品應(yīng)用  WB=1:100-500 Elisa=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1/20-1/100
（石蠟切片需做抗原修復(fù)）Not yet tested in other applications.
 Optimal dilutions/concentrations should be determined by the end user. 
研究領(lǐng)域  細(xì)胞生物 免疫學(xué) 染色質(zhì)和核信號 轉(zhuǎn)錄調(diào)節(jié)因子 
保存  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

公司提供的 已被國內(nèi)外廣大科研工作者使用，廣泛用于分子生物學(xué)、免疫學(xué)等試驗(yàn)中。

相關(guān)產(chǎn)品：
Anti-BFGF/FGF-2   堿性成纖維細(xì)胞生長因子抗體
Anti-BGP（Osteocalcin/Bone Gla-protein）   骨保護(hù)蛋白/骨鈣素抗體
Anti-Bid （BH3 interacting domain death agonist）   BH3結(jié)構(gòu)域凋亡誘導(dǎo)蛋白抗體
Anti-BIN1（Bridging integrator protein-1）   橋連整合因子蛋白抗體
Anti-Bim（Bcl-2 interacting mediator of cell death）   細(xì)胞死亡調(diào)解子抗體
Anti-BIRC5/Survivin variant   細(xì)胞凋亡抑制因子5抗體
Anti-BK channel （stretch-activated Kca channel）   BK通道蛋白抗體
Anti-BKCa channels（calcium-activated potassium channel）   鈣激活鉀通道蛋白抗體
Anti-BMP2 （bone morphogenetic protein 2）   骨形態(tài)發(fā)生蛋白-2抗體
Anti-BMP4（bone morphogenetic protein 4）   骨形態(tài)發(fā)生蛋白4抗體


您感興趣的產(chǎn)品PRODUCTS YOU ARE INTERESTED IN

環(huán)保在線 設(shè)計(jì)制作，未經(jīng)允許翻錄必究 .? ? ? Copyright(C)?2021 http://www.zuisujiong.cn,All rights reserved.

以上信息由企業(yè)自行提供，信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé)，環(huán)保在線對此不承擔(dān)任何保證責(zé)任。 溫馨提示：為規(guī)避購買風(fēng)險(xiǎn)，建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。

會(huì)員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗(yàn)證碼

收藏該商鋪

請 登錄 后再收藏

提示

您的留言已提交成功！我們將在第一時(shí)間回復(fù)您~
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |